User login
Food and Drug Administration (FDA) Commissioner Robert Califf, MD, will deliver a keynote address on the opening morning of the NORD Rare Diseases and Orphan Products Breakthrough Summit to take place Oct. 17 and 18 in Arlington Virginia. Approximately one-third of the novel new drugs approved by FDA in recent years have been “orphan” drugs for rare diseases.
Dr. Califf will be joined on the program agenda by more than 25 additional FDA speakers, including Janet Woodcock, MD, Director of FDA’s Center for Drug Evaluation and Research, and Peter Marks, MD, PhD, Director of FDA’s Center for Biologics Evaluation and Research.
On Day Two of the conference, Kate Rawson, Senior Editor at Prevision Policy, will provide the morning keynote with a look ahead at possible implications of the national election for the rare disease community. The NORD Summit attracts medical professionals, patient advocates, and others to examine issues related to rare disease research, diagnosis, treatment, and patient access to care. The conference is open to all. Click here to view the agenda.
Food and Drug Administration (FDA) Commissioner Robert Califf, MD, will deliver a keynote address on the opening morning of the NORD Rare Diseases and Orphan Products Breakthrough Summit to take place Oct. 17 and 18 in Arlington Virginia. Approximately one-third of the novel new drugs approved by FDA in recent years have been “orphan” drugs for rare diseases.
Dr. Califf will be joined on the program agenda by more than 25 additional FDA speakers, including Janet Woodcock, MD, Director of FDA’s Center for Drug Evaluation and Research, and Peter Marks, MD, PhD, Director of FDA’s Center for Biologics Evaluation and Research.
On Day Two of the conference, Kate Rawson, Senior Editor at Prevision Policy, will provide the morning keynote with a look ahead at possible implications of the national election for the rare disease community. The NORD Summit attracts medical professionals, patient advocates, and others to examine issues related to rare disease research, diagnosis, treatment, and patient access to care. The conference is open to all. Click here to view the agenda.
Food and Drug Administration (FDA) Commissioner Robert Califf, MD, will deliver a keynote address on the opening morning of the NORD Rare Diseases and Orphan Products Breakthrough Summit to take place Oct. 17 and 18 in Arlington Virginia. Approximately one-third of the novel new drugs approved by FDA in recent years have been “orphan” drugs for rare diseases.
Dr. Califf will be joined on the program agenda by more than 25 additional FDA speakers, including Janet Woodcock, MD, Director of FDA’s Center for Drug Evaluation and Research, and Peter Marks, MD, PhD, Director of FDA’s Center for Biologics Evaluation and Research.
On Day Two of the conference, Kate Rawson, Senior Editor at Prevision Policy, will provide the morning keynote with a look ahead at possible implications of the national election for the rare disease community. The NORD Summit attracts medical professionals, patient advocates, and others to examine issues related to rare disease research, diagnosis, treatment, and patient access to care. The conference is open to all. Click here to view the agenda.